Wall Street indices closed lower for a third consecutive session as healthcare stocks declined and investors cashed in gains following a strong equity market performance this year. The S&P 500, which had risen 11% in 2019, faced challenges breaking past the 2,800-point threshold, closing below that level in five of the last six trading days.
The decline came amid uncertainty over U.S.-China trade negotiations and concerns about the Federal Reserve's monetary policy. Analysts noted that the market had already priced in optimism about a potential trade deal, leading to profit-taking activities. 'The S&P 500 has gained so much in a short period, and the risk/reward profile is shifting,' said Aaron Clark, a portfolio manager at GW&K Investment Management.
The healthcare sector was the primary drag on the benchmark index, falling 1.6% as major pharmaceutical companies like UnitedHealth Group, Amgen, and Pfizer declined between 1.2% and 2.8%. This followed the unexpected resignation of U.S. FDA Commissioner Scott Gottlieb, which raised regulatory concerns.
Energy stocks also declined 1.66%, with Exxon Mobil falling 1.7% after announcing increased capital spending plans. In contrast, the materials sector rose 0.39% after Goldman Sachs upgraded LyondellBasell Industries NV to 'buy,' sending its shares up 6.1%.
General Electric Co. shares tumbled 8% after the company warned of negative cash flow from its industrial operations in 2019. The Federal Reserve's Beige Book economic report, due at 2 p.m. ET, remained a key focus for investors navigating volatile markets.
